A review of epidemiological data on epilepsy, phenobarbital, and risk of liver cancer
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Phenobarbital is not genotoxic, but has been related to promotion of liver cancer (as well as inhibition) in rodents. In October 2012, we carried out a systematic literature search in the Medline database and searched reference lists of retrieved publications. We identified 15 relevant papers. Epidemiological data on epileptics/anticonvulsant use and liver cancer were retrieved from eight reports from seven cohort (record linkage) studies of epileptics, and data on phenobarbital use from a pharmacy-based record linkage investigation of patients treated with phenobarbital (three reports), plus a case-control study nested in one of the cohort studies and including information on phenobarbital use. Of the studies of cancer in epileptics, two showed no excess risk of liver cancer. A long-term (1933-1984) Danish cohort study of epileptics found relative risks (RRs) of 4.7 [95% confidence interval (CI) 3.2-6.8] of liver cancer and of 2.2 (95% CI 1.2-3.5) of biliary tract cancers. Such apparent excess risks could, however, be largely or completely attributed to thorotrast, a contrast medium used in the past in epileptic patients for cerebral angiography. A Finnish cohort study of epileptics obtained an RR of 1.7 (95% CI 1.2-2.4). Such an apparent excess risk, however, was not related to phenobarbital or to any specific anticonvulsant drug. The long-term follow-up of two UK cohorts found some excess risk of liver cancer among severe, but not among mild, epileptics. Some excess risk of liver cancer was also found in cohort studies of patients hospitalized for epilepsy in Sweden and Taiwan, in the absence, however, of association with any specific drugs. A UK General Practice database, comparing epileptics treated with valproate with unexposed ones, found a very low incidence of liver cancer. Of the studies of cancer in patients treated with phenobarbital, a large US pharmacy-based cohort investigation showed no excess risk of liver cancer. In a case-control study, nested in the Danish cohort of epileptics, no association was observed between phenobarbital and liver cancer among patients who had not received thorotrast (RR=1.0 for liver and 0.8 for biliary tract cancers). Thus, some, although not all, studies reported excess risk of all cancers and liver cancer in severe, but not in milder epileptics. There is no evidence of a specific role of phenobarbital in human liver cancer risk, but data on the topic are limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality of Epilepsy in Developed Countries: A Review
Forsgren, L., Hauser, W. A., Olafsson, E., Sander, J. W. A. S., Sillanpää, M., & Tomson, T. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.00403.x · Cited by 282 · cited 2×
“This is attributed to deprivation and consequent unfavorable lifestyle factors among severe (hospitalized) epileptics (Forsgren et al., 2005; Neligan et al., 2010), although data on lifestyle factors are scarce and inconsistent, particularly for outpatients (Cockerell et al.”
Background
Cited by
Elcombe, C. R., Peffer, R. C., Wolf, D. C., Bailey, J., Bars, R., Bell, D., Cattley, R. C., Ferguson, S. S., Geter, D., Goetz, A., et al. (2014) · Critical Reviews in Toxicology · doi:10.3109/10408444.2013.835786 · Cited by 265
Hong, M., Li, S., Tan, H., Wang, N., Tsao, S.-W., & Feng, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226126 · Cited by 194
“The five year survival rate of primary liver cancer is only 17% in the United States in 2014 and even lower in developing countries [150].”
BackgroundChang, E. T., Adami, H.-O., Boffetta, P., Cole, P., Starr, T. B., & Mandel, J. S. (2014) · Critical Reviews in Toxicology · doi:10.3109/10408444.2014.905767 · Cited by 180
“Furthermore, despite the widespread use of phenobarbital as a drug in humans, a recent review of epidemiological studies of phenobarbital concluded that there was no evidence for a specifi c role of phenobarbital in human liver cancer risk (La Vecchia and Negri, 2014).”
BackgroundActivating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis
Dong, B., Lee, J.-S., Park, Y.-Y., Yang, F., Xu, G., Huang, W., Finegold, M. J., & Moore, D. D. (2015) · Nature Communications · doi:10.1038/ncomms6944 · Cited by 97
Felter, S. P., Foreman, J. E., Boobis, A., Corton, J. C., Doi, A. M., Flowers, L., Goodman, J., Haber, L. T., Jacobs, A., Klaunig, J. E., et al. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.11.003 · Cited by 80
“This conclusion is supported by data from a number of epidemiological studies conducted in human populations chronically exposed (e.g., for decades) to PB in which there is no evidence for increased liver tumor risk (La Vecchia and Negri, 2014).”
ResultNiu, B., Coslo, D. M., Bataille, A. R., Albert, I., Pugh, B. F., & Omiecinski, C. J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky692 · Cited by 37
“However, detailed roles for CAR’s participation in the carcinogenic process are not well understood and are the subject of some controversy in that chronic human exposures to PB, a known CAR activator, have not been associated with any detectable increase in human liver cancer incidence (14,15).”
Background
Metadata
- Authors
- La Vecchia, C., & Negri, E.
- Venue
- European Journal of Cancer Prevention
- Published
- 2014-01
- Volume
- 23
- Issue
- 1
- Pages
- 1-7
- ISSN
- 0959-8278 (ISSN-L)
- OpenAlex
- W2017710583
- Cited by
- 66
- References
- 1
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.